| Literature DB >> 28138126 |
Jie Zhou1, Maowei Ni2, Xia Liu1, Zeming Ren1, Zhiguo Zheng2.
Abstract
BACKGROUND Wound healing in chronic diabetic mellitus is mainly associated with the management of angiogenesis. The angiogenic mechanism of vascular endothelial growth factor (VEGF) has been widely studied in the context of diabetic ulcers. The aim of this study was to investigate the wound-healing potential of curcumol in streptozotocin-induced diabetic rats. MATERIAL AND METHODS Sixty male SD (Sprague Dawley) rats were purchased and randomly assigned into four groups: a control group and a model group treated with blank ointment, a high-dose curcumol group, and a low-dose curcumol group. The number of animals in each group was 15. Diabetes was induced by an intraperitoneal injection of streptozotocin. Two cutaneous wounds were incised at the dorsal region of all the experimental animals. Wound healing was assessed for all animal groups by observing the rate of wound closure. The expression of VEGF at the wound sites was studied by immunohistochemical staining to evaluate the vascular endothelial cell reaction. VEGF protein and related mRNA levels were analyzed by Western blotting and RT-PCR (reverse transcription-polymerase chain reaction). RESULTS Curcumol treatment significantly increased the rates of wound closure in treated animals, and hence wound healing was drastically enhanced for treatment groups compared to control groups. Histological observations and related mRNA and protein levels showed a higher VEGF expression in the treatment groups. CONCLUSIONS Our analyses clearly suggested that the observed enhancement in wound healing as a result of curcumol administration was attributable to VEGF-mediated angiogenesis.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28138126 PMCID: PMC5297326 DOI: 10.12659/msm.902859
Source DB: PubMed Journal: Med Sci Monit ISSN: 1234-1010
Specific primer sequences for RT-PCR.
| Gene | Forward 5′-3′ | Reverse 5′-3′ |
|---|---|---|
| VEGFR1 | TTTAAAAGGCACCCAGCACAT | TTACTCACCATTTCAGGCAAAGAC |
| VEGFR2 | GGCCCAATAATCAGAGTGGCA | TGTCATTTCCGATCACTTTTGGA |
| GAPDH | GGGAAACTGTGGCGTGAT | AAAGGTGGAGGAGTGGGT |
Figure 1(A, B) Blood glucose and body weights of different groups during the study period.
Figure 2(A, B) Wound closure of different groups (* p<0.05 compared to model group; ** p<0.01 compared to model group).
Figure 3VEGF immunohistochemistry: Effect of curcumol treatment on angiogenesis as shown by the brownish appearance of vascular endothelial cell marker on day 14: (A) group 1; (B) group 2; (C) group 3; (D) group 4. Magnification 200×. (E) Ratio of VEGF positive expression (%). (** p<0.01 compared to model group; *** p<0.001 compared to model group).
Figure 4(A,B) VEGF expression as measured by Western blot analysis and quantified by densitometry, normalized by β-actin levels, and expressed as a percentage of the model group. (C) qRT-PCR of VEGFR1 and VEGFR2. (* p<0.05 compared to model group; ** p<0.01 compared to model group; *** p<0.001 compared to model group).